# US 2016/0252534 A1 · Methodologies and Reagents for Detecting Fibrinolysis and Hyperfibrinolysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252534 A1
- Document ID: US20160252534A1
- Status: Published application
- Kind: A1
- Application number: 15/149,868
- Filed: 2016-05-09
- Published: 2016-09-01
- Earliest claimed: 2014-05-05
- Assignees: Haemonetics Corporation; The Regents of the University of Colorado, a body corporate
- Applicants: Haemonetics Corporation; The Regents of the University of Colorado, a body corporate
- Inventors: Michael P. Chapman; Ernest E. Moore; Katherine M. Norem
- Web page: https://patentgrep.com/patent/US20160252534A1

## CPC

- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- C12Q 1/56: involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- G01N 33/49: Blood {(chemical methods for determining blood cell populations G01N33/5094; chemical analysis of blood groups or blood types G01N33/80)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

In some embodiments, the invention provides a container adapted for detecting hyperfibrinolysis or fibrinolysis in a blood sample using viscoelastic analysis comprising an interior having a coating comprises an inhibitor of fibrinolysis.

## Claims

### Claim 1

A container adapted for detecting hyperfibrinolysis or fibrinolysis in a blood sample using viscoelastic analysis comprising an interior having a coating comprises an inhibitor of fibrinolysis.

### Claim 2 (depends on 1)

The container of claim 1, wherein the inhibitor of fibrinolysis is tranexamic acid.

### Claim 3 (depends on 1)

The container of claim 1, wherein the inhibitor of fibrinolysis is selected from the group consisting of an aminocaproic acid (ε-aminocaproic acid), and aprotinin.

### Claim 4 (depends on 1)

The container of claim 1, wherein the viscoelastic analysis is performed using a TEG thromboelastography analyzer system or in a ROTEM thromboelastometry analyzer system.

### Claim 5 (depends on 1)

The container of claim 1, wherein the inhibitor of fibrinolysis is formulated with sugar in the coating.

### Claim 6 (depends on 1)

The container of claim 1, wherein the inhibitor is formulated with sodium azide in the coating.

### Claim 7 (depends on 1)

The container of claim 1, wherein the coating further comprises an inhibitor of platelet function.

### Claim 8 (depends on 7)

The container of claim 7, wherein the inhibitor of platelet function is a glycoprotein IIb/IIIa receptor inhibitor.

### Claim 9 (depends on 8)

The container of claim 8, wherein the glycoprotein IIb/IIIa receptor inhibitor is selected from the group consisting of abciximab, eptifibatide, and tirofiban.

### Claim 10 (depends on 7)

The container of claim 7, wherein the inhibitor of platelet function is an adenosine diphosphate (ADP) receptor inhibitor, adenosine reuptake inhibitor, or a thromboxane inhibitor.

### Claim 11 (depends on 7)

The container of claim 7, wherein the inhibitor of platelet function is cytochalasin D.

### Claim 12 (depends on 1)

The container of claim 1, wherein the container is located on a cassette, wherein the cassette further comprises a second container.